|1.||Toretsky, Jeffrey A: 20 articles (03/2015 - 10/2004)|
|2.||Kovar, Heinrich: 18 articles (11/2015 - 08/2002)|
|3.||Uren, Aykut: 9 articles (01/2012 - 10/2004)|
|4.||Üren, Aykut: 8 articles (11/2015 - 01/2011)|
|5.||Erkizan, Hayriye V: 8 articles (03/2015 - 07/2009)|
|6.||Aryee, Dave N T: 8 articles (11/2014 - 08/2002)|
|7.||Iwamoto, Yukihide: 8 articles (07/2012 - 04/2003)|
|8.||Ban, Jozef: 7 articles (11/2014 - 04/2005)|
|9.||Stamenkovic, Ivan: 7 articles (11/2014 - 12/2005)|
|10.||Li, Xu: 7 articles (07/2012 - 04/2003)|
02/01/1998 - "Molecular diagnosis of Ewing tumors: improved detection of EWS-FLI-1 and EWS-ERG chimeric transcripts and rapid determination of exon combinations."
04/20/2010 - "The type 1 EWS-FLI1 transcript is created as a result of fusion between exons 7 of EWS and 6 of FLI1, and retrospective studies have reported that type 1 tumors are associated with an improved outcome. "
11/01/2008 - "To study the effects of the fusion gene EWS-FLI1 on development and tumor formation, a transgenic mouse model was created. "
11/01/2008 - "In this study we explored the role of EWS-FLI1 in tumor differentiation using an embryonal carcinoma cell line P19 as a model, with forced expression of EWS-FLI1 in these cells. "
06/01/2005 - "The present study shows that the neural phenotype of Ewing's tumors is attributable to the EWS-FLI1 expression and the resultant phenotype resembles developing neural crest. "
|2.||Sarcoma (Soft Tissue Sarcoma)
09/15/2015 - "EWS-FLI1 binds near the transcription start site of SLFN11 promoter and acts as a positive regulator of SLFN11 expression in Ewing sarcoma cells. "
09/15/2015 - "SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma."
07/01/2015 - "We illustrate i-cisTarget on various Ewing sarcoma datasets to identify EWS-FLI1 targets starting from ChIP-seq, differential ATAC-seq, differential H3K27ac and differential gene expression data. "
03/17/2015 - "EWS-FLI1 is an Ewing sarcoma (ES) oncoprotein with an interactome that we demonstrate to have multiple partners in spliceosomal complexes. "
03/11/2015 - "Consequently we propose that aberrant cell cycle activation in Ewing sarcoma is due to the de-repression of E2F targets as a consequence of transcriptional induction and physical recruitment of E2F3 by EWS-FLI1 replacing E2F4 on their target promoters. "
|3.||Ewing's Sarcoma (Sarcoma, Ewing)
12/26/2014 - "Synthesis and structure-activity relationship studies of small molecule disruptors of EWS-FLI1 interactions in Ewing's sarcoma."
01/01/2015 - "Collectively, these results indicated that ectopic expression of the Ews-Fli1 oncogene stimulated apoptotic signals, and suggested an important relationship between oncogenic signals and cellular context in the cell-of-origin of Ewing's sarcoma. "
08/15/2013 - "MiR-30a-5p connects EWS-FLI1 and CD99, two major therapeutic targets in Ewing tumor."
01/01/2012 - "Junction region can be exploited further as target for drug development in future to specifically target EWS-FLI1 in Ewing's Sarcoma."
01/01/2012 - "Ectopically expressing this region in Ewing's sarcoma cells inhibited tumorigenicity, and EWS-FLI1 target genes indicating a dominant negative biological effect. "
08/01/2003 - "In vitro suppression of EWS-FLI1 expression will allow to define the phenotypic characteristics of dormant tumor cells that may give rise to late relapses, enabling improved diagnosis and treatment even of minimal residual disease."
01/01/2000 - "[Minimal residual disease in bone marrow in patients with Ewing's sarcoma detected by RT-PCR amplification of EWS-FLI-1 fusion gene transcript]."
11/10/2015 - "Herein, we tested in vivo therapeutic efficacy and potential side effects of YK-4-279 in the transgenic mouse model with EWS-FLI1 induced leukemia. "
11/10/2015 - "Transgenic expression of EWS-FLI1 in mice promotes high penetrance erythroid leukemia with dense hepatic and splenic infiltrations. "
11/10/2015 - "YK-4-279 effectively antagonizes EWS-FLI1 induced leukemia in a transgenic mouse model."
01/01/2003 - "The most frequent fusion product associated with EFT, EWS-FLI1, is the founding member of a whole class of similarly structured chimeric proteins associated with a variety of human sarcomas and also specific leukemias. "
|2.||Proteins (Proteins, Gene)
|3.||Small Interfering RNA (siRNA)
|4.||trabectedin (ecteinascidin 743)
|6.||RNA-Directed DNA Polymerase (Reverse Transcriptase)
|7.||Biological Markers (Surrogate Marker)
|8.||Proto-Oncogene Proteins c-ets
|10.||Transcription Factors (Transcription Factor)
|3.||Heterologous Transplantation (Xenotransplantation)
|5.||Drug Therapy (Chemotherapy)